Perrigo Company PLC
http://www.perrigo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Perrigo Company PLC
US Consumer Health Q2 Earnings Preview: If Not For Headwinds, Tailwinds Would Be Trending
Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.
Congressional Appropriators Encourage FDA Guidance On Contraceptive OTC Switches
House and Senate reports again reference sunscreen but add admonishment that FDA “harmonize its approach with international testing standards.” Item exclusive to House report encourages guidance for drug firms on successfully submitting an application for Rx-to-OTC switch of an oral contraceptive.
Stabilizing Formula Business ‘First And Foremost’ For Perrigo To Reach Sustainable Growth
Perrigo’s adjusted operating income from formula business in 2023 was around half the $140m it expects. Level won’t be reached in 2024 but it’s “well on track to recapturing” that amount in 2025 and to “capturing all of that plus in 2026,” says CEO Patrick Lockwood-Taylor.
Opill Launch Delivers For Perrigo While Growing Pains Slow Overall First-Quarter Results
Perrigo spares little about Opill’s launch, advertising and outlook in Q1 earnings briefing, but management also makes clear it’s a large firm and some other segments of its global consumer health products business are holding back overall results.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Agis Industries
- Chemagis
- Clay-Park Labs
- Cobrek Pharmaceuticals
- Elan Corporation
- JB Laboratories
- Onclave Therapeutics Limited
- Omega Pharma Invest N.V.
- Paddock Laboratories
- Omega Pharma Invest N.V.
- Ranir Global Holdings LLC
- Rosemont Pharmaceuticals Ltd.
- Unico Holdings Inc.
- Velcera, Inc.
- Geiss, Destin & Dunn, Inc.
- High Ridge Brands
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice